Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients - Archive ouverte HAL Access content directly
Conference Papers Year :

Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients

Meeting Abstract: 745P

, , , , , , , , , (1, 2) , ,
1
2
A Awada
  • Function : Author
J Harding
  • Function : Author
Nuria Kotecki
  • Function : Author
P Aftimos
  • Function : Author
T. Decaens
  • Function : Author
C. Dreyer
  • Function : Author
Christelle Ansaldi
  • Function : Author
M Rachid
  • Function : Author
C. Serdjebi
  • Function : Author
G Abou-Alfa
  • Function : Author
E Raymond
  • Function : Author
Not file

Dates and versions

hal-02463220 , version 1 (31-01-2020)

Identifiers

  • HAL Id : hal-02463220 , version 1

Cite

A Awada, J Harding, Nuria Kotecki, P Aftimos, T. Decaens, et al.. Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients. 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Sep 2019, Barcelona, Spain. pp.286. ⟨hal-02463220⟩

Collections

CNRS UNIV-AMU
10 View
0 Download

Share

Gmail Facebook Twitter LinkedIn More